Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study

Abstract Introduction Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 in Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed to characterise the effectiveness of U...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Louis Bessette, Jonathan Chan, Andrew Chow, Larissa Lisnevskaia, Nicolas Richard, Pierre-Andre Fournier, Dalinda Liazoghli, Tanya Girard, Derek Haaland
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2024-03-01
Serija:	Rheumatology and Therapy
Teme:	Clinical trial Janus kinase inhibitor Phase 4 Real-world effectiveness Rheumatoid arthritis Upadacitinib
Online dostop:	https://doi.org/10.1007/s40744-024-00651-8
Oznake:	Označite Brez oznak, prvi označite!